Table 1.
General characteristic of the study subjects for validation study.
| CLI | Non - CLI | P | |
|---|---|---|---|
| Case, n | 26 | 30 | -- |
| Age, years | 64.54±2.83 | 61.50 (57.50-69.25) | 0.806‡ |
| T2D Duration, years | 15.85±1.48 | 9.00 (8.00-14.25) | 0.003‡ |
| Women, % | 13, (50.00) | 15, (50.00) | 1.000† |
| Hyperlipidemia, % | 10, (38.46) | 10, (33.33) | 0.690† |
| Hypertension, % | 15, (57.69) | 9, (30.00) | 0.037† |
| Smoking, % | 15, (57.69) | 8, (26.67) | 0.019† |
| ABI | 0.58±0.04 | 1.11±0.01 | 0.000 |
| BMI, kg/m2 | 24.20 (23.30-26.23) | 25.54±0.53 | 0.528‡ |
| CAD, % | 7, (26.92) | 8, (26.67) | 0.983† |
| Statin use, % | 5, (19.23) | 4, (13.33) | 0.549† |
| Antihypertensive treatment use, % | 7, (26.92) | 5, (16.67) | 0.351† |
| Metformin use, % | 21, (80.77) | 23, (76.67) | 0.709† |
| FPG, mmol/L | 9.74 (8.82-14.40) | 7.22 (6.13-8.90) | 0.001‡ |
| HbA1c, % | 8.95 (7.88-9.63) | 6.90 (6.50-9.05) | 0.002‡ |
| HDL-C, mmol/L | 1.08±0.05 | 1.16 (0.89-1.31) | 0.274‡ |
| LDL-C, mmol/L | 2.61±0.18 | 2.64±0.15 | 0.920 |
| TG, mmol/L | 1.50 (1.06-1.88) | 1.29 (0.92-1.86) | 0.862‡ |
| TC, mmol/L | 2.86 (2.59-4.03) | 4.31±0.18 | 0.012‡ |
| Apo A, g/L | 1.16 (1.02-0.28) | 1.14 (1.06-1.30) | 0.172‡ |
| Apo B, g/L | 0.92±0.04 | 0.85±0.04 | 0.286 |
| Cr, μmol/L | 77.50 (58.00-107.45) | 65.70 (55.75-72.25) | 0.046‡ |
| BUN, mmol/L | 5.61 (4.60-7.60) | 6.15±0.41 | 0.366‡ |
| UA, mmol/L | 324.60±13.53 | 324.29±19.39 | 0.899 |
| hsCRP, mg/dL | 0.36 (0.19-1.37) | 0.65 (0.27-2.53) | 0.405‡ |
ABI, Ankle brachial index; BMI, body mass index; CAD, coronary artery disease; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; Apo A, Apolipoprotein A; Apo B, Apolipoprotein B; Cr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; hsCRP, high-sensitivity C-reactive protein. Data is expressed as mean±SEM, median (interquartile range), or percentage. Significant values are marked in italic. Continuous variables were compared by the Fisher-Pitman Permutation test, and categorical variables were compared by Fisher's exact test in the miRNA array cohort; however, the validation cohort was analyzed using †) χ2 test or ‡) Mann-Whitney U test, and the others were analyzed using t-tests.